Comparative Efficacy and Safety of Immunosuppressive Strategies in Kidney Transplantation: A Network Meta-analysis
Network meta-analyses comparing immunosuppressive strategies in kidney transplantation indicate that lymphocyte-depleting induction agents such as alemtuzumab and rabbit antithymocyte globulin reduce acute rejection more than interleukin-2 receptor antagonists, but at the cost of more infectious complications.
Background
Effective immunosuppression underpins kidney transplant success, but the optimal induction and maintenance regimen remains debated because agents differ in their balance between preventing rejection and causing infection, diabetes, and other harms. Network meta-analysis allows simultaneous comparison and ranking of multiple immunosuppressive strategies using direct and indirect evidence from randomized trials.
Key findings
Across network meta-analyses of induction therapy, alemtuzumab and rabbit antithymocyte globulin were the most effective agents for reducing biopsy-proven acute rejection compared with interleukin-2 receptor antagonists such as basiliximab; in one analysis the odds ratios for rejection versus basiliximab were 0.45 for alemtuzumab and 0.63 for rabbit antithymocyte globulin. However, rabbit antithymocyte globulin was associated with more bacterial infection (odds ratio about 1.8). For maintenance therapy, evidence generally showed no single regimen superior across all outcomes, with tacrolimus-based combinations favored for reducing rejection but carrying a higher risk of new-onset diabetes.
Clinical implications
These comparative analyses suggest that more potent depleting induction lowers acute rejection but increases infectious risk, so agent selection should be individualized to a recipient's immunologic risk and comorbidity profile. No maintenance regimen is uniformly best, reinforcing a tailored approach that weighs rejection prevention against infection, metabolic, and other adverse effects.
Category
Transplant
Source
Cureus
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.